Join        Login             Stock Quote

Isis Pharmaceuticals: Antisense Value

 November 27, 2012 05:16 PM

By John McCamant, editor The Medical Technology Stock Letter

Isis Pharmaceuticals (ISIS) has had a lots of news. The first was the announcement that the company will receive $1.1 million from Alnylam as its portion of the upfront fees from a collaboration with Genzyme.  

The company also announced that they will receive a $1.25 million contingent payment from Pfizer triggered by Pfizer's decision to advance EXC 001 into a Phase II trial. Pfizer's commitment to advancing EXC 001 is a testament to ISIS' business strategy investment.

The market opportunity to treat hypertrophic scars is very large and Pfizer has the drug development expertise and global commercial infrastructure to support the continued advancement of EXC 001, which ISIS could not do on their own.  

The ability to develop a drug development candidate to proof of concept and then partner it on attractive terms is a winning formula for ISIS and their shareholders.

ISIS also had a few pieces of positive clinical news. The company announced the initiation of a Phase Ib/IIa trial evaluating ISIS-SMNRx in children with spinal muscular atrophy (SMA). SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness and is the most common genetic cause of infant mortality.  

Under the terms of the January 2012 agreement, ISIS is responsible for global development and Biogen has the option to license the compound until completion of the first successful Phase 2/3 trial.

The company also announced the initiation of a Phase II comparator-controlled trial evaluating ISIS-FXIRx in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty (TKA).  

ISIS-FXIRx inhibits the production of Factor XI, a coagulation factor produced in the liver that is involved in the formation of clots.  

The combination of robust anti-thrombotic activity with an improved safety profile to currently available anticoagulants could be broadly useful in many therapeutic settings where thrombosis is a serious problem.  

ISIS has also announced that preliminary data from the Phase I trial of ISIS-STAT3Rx in patients with cancer were  presented at the Oligonucleotide Therapeutics Society in Boston.  

The early data on ISIS-STAT3Rx is intriguing as it suggests that this drug development candidate can produce responses in refractory patients with advanced cancer who have failed to respond to other therapies.

ISIS continues to create significant long-term value for their shareholders despite Wall Street's continued reservations regarding antisense technology. ISIS is a buy under $12.  



Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageWorld Growth: Mediocre or Pathetic?

The recent disappointing performance of the world economy has been labelled as the "new mediocre" by read on...

article imageSurvey Data For US Services Sector Hint At Mild Q2 Rebound

Yesterday’s discouraging numbers on job growth in April via the ADP Employment Report raise doubts about a read on...

article imageADP: US Job Growth Stumbled In April

Employment growth at US companies slowed in April to the weakest gain in three years, according to this read on...

article imageBogle Says Indexing Destined To Win The Battle Of The Quants

Vanguard founder John Bogle gave a powerful speech last month at the Q Group’s Spring Seminar that lays out read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.